AHA 2024: Powerful Medical Makes History as First to Win Both Best Science Startup and Overall Winner Awards
CHICAGO, Nov. 27, 2024 /PRNewswire/ -- Powerful Medical became the first company to win both the Best Science Startup and...
CHICAGO, Nov. 27, 2024 /PRNewswire/ -- Powerful Medical became the first company to win both the Best Science Startup and...
Join Cleerly Leadership for Live Demonstrations on Advanced Imaging Solutions for Personalized Heart Disease Care DENVER, Nov. 26, 2024 /PRNewswire/...
Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions...
SAN FRANCISCO, Nov. 19, 2024 /PRNewswire/ -- Avive Solutions is proud to announce its partnership with Academy Safe, a non-profit organization...
Women are the key decision makers in 80% of all healthcare choices, yet many brands fail to accurately portray them...
Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy...
Advancing its Going for Zero mission, OMRON innovation makes AFib screening an integral part of the brand's routine home blood...
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to...
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding...
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present...
SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- On July 16, 2024, a life-saving event unfolded when a trained citizen volunteer...
Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans...
RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing...
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual...
The grant, which is awarded to companies developing significantly impactful technologies with the potential to change clinical practice, will support...
The digital twin AI platform helps patients safely eliminate blood pressure medications and sustain normal blood pressure MOUNTAIN VIEW, Calif.,...
KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a...
Hello Heart selects Amwell platform to extend its reach across patient populationsBOSTON and MENLO PARK, Calif., Oct. 08, 2024 (GLOBE...
Patients identified with reduced ejection fraction using Eko Health AI were twice as likely to experience heart attacks, heart failure,...
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding...